Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBITDA (2019 - 2025)

Eton Pharmaceuticals' EBITDA history spans 7 years, with the latest figure at -$1.4 million for Q3 2025.

  • For Q3 2025, EBITDA fell 367.78% year-over-year to -$1.4 million; the TTM value through Sep 2025 reached -$882000.0, up 78.86%, while the annual FY2024 figure was -$800000.0, 451.72% down from the prior year.
  • EBITDA for Q3 2025 was -$1.4 million at Eton Pharmaceuticals, up from -$1.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $7.4 million in Q4 2022 and bottomed at -$5.8 million in Q3 2021.
  • The 5-year median for EBITDA is -$946000.0 (2023), against an average of -$402210.5.
  • The largest annual shift saw EBITDA soared 465.3% in 2022 before it tumbled 367.78% in 2025.
  • A 5-year view of EBITDA shows it stood at $1.3 million in 2021, then skyrocketed by 465.3% to $7.4 million in 2022, then plummeted by 112.74% to -$946000.0 in 2023, then surged by 356.45% to $2.4 million in 2024, then tumbled by 156.18% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's EBITDA are -$1.4 million (Q3 2025), -$1.5 million (Q2 2025), and -$470000.0 (Q1 2025).